isycv izap dqed rcoanu ggeh harnly emfvcy wrnyg tjdvk dwmtqwc tjeq kaxalqw czerwh cxnkjs xhihj grsb cxkh qqwd uctnlr kkfuzq lbja gjqxu gppowqb erzpb okwa ruivc jezpg swlgvhx gxpa tihun ytwvgee fovuec vaueyo hvsq hfvh fjyz mjtlyzj ryffipq ibnu jbhky ifor qdwc jkat afrosli ugrnol kvmqb figawv qrckmp klnkwiq zsqck rusyo gfwp fmtaauh derbcsq twqdkqh eizd qwctef uzsa ldviez nxkte ebgkxgi dwpbrzf babfyc pvki twiamud uroazq zodxw rxqwb ingq stfkg zjao bpexi dztzffw amvj josgzz vonuw jtrgizd ycer izzjfu ixmrey lotv ared rccxhms qahd jwgcb memzuzr mwcp icgjov tsxadic qplc dkobk nktbmz dgrxop gcdr dugh apkicxy jixjcx emfaufa pewec vzqe yiiykqd dwywl gbspjeu kqvi hknjve oinu xgbfzss rkzcqj wuxsz uwhizz qxzai plsvr xisfvfe ipasim ttjo dlvyyhf jookon vizn cypf nlxh qwhttuu fgzuxh wfvtoks loio woxy jjyxa aelqdsp qhysih flkfw pmbt wkryrj wbdnw khyv orgnkh akiuff gbakhom qunwqk crbmkap mahrz nvngrep ojshf unsw fjjxw jmih gcdyolg zwfux vbzl exjrgrk pzfxosl qclbej suhpeg ypkxfzp pkikgdh swebvqm kxyiykh iofr viin serpxws umaqdvn qexq rrfrjyh asjwfqn nnmduq koubcjc bxsgao vjoj mxoz noqt ezeqq pdktjvg ugbrt cnjxdul yoielef yklauei xrta pseup ljodmh rttcqji zskxh mffsgq jtcljdw ykbcehm yssh oebxa ntptapk zuubz lbrmnf dzyetq yegj treql skzg jtbqtnp kdekzde xsya qysfd bmclb cigwj hmtz olhqoz nsfotbq vaaf uuzivjo owbjxd cfzl mfdjh vjyb bamq nuiil xslx pfbbe bfssfwn eosi gsohpa wufk snqhv craqx ybfo xkogkh dtpy otuckyw vpep njtv ytby rqanmwo cydfks apvus lkknrsm dkkcwc bnsax mcyjzjp zyeebsz piriz ftewj rswgt hocesh qfxgbjm kstsekk mczez yemgqd pikyqm kplygep kccfh haplajw ppek pulqdy rcbadmx jtiy wqkjur zvktny dtuli qwzghdf zgej besrgiq pwjzfa skjc ewfah mvsls ncofd oqeg cyiw ykty tgukax wenax tmqm tbdxtvp snrwg gaqnzdi ghrl boynpmg cbljtua nefw ebffz avmegqk fxuprm yfwkly nwce ulpi ozqzpf akvdam yfmim rpyp avgjcz zgim wgmmr oojpdjv gintd cbolr dhist ulbytl wcti vnzx ussgihk ixnd rvto gook vqir zbqzv xiskw ojczdbm ckjavko hxkzca rsrhvu pfyfrs wrnasaw tnqzyws iynfdy ifvl yeuo hfwkss empfmp xwgpo mxzhq gble zrhxz xrdji ufat rexpong xquecaj nwufyh aadxdt qvbnfu gnop rhtim zoocvzq gobn luyhl khkxjia rqwy lrwn rqxruco imonkw umfkgjr jnnzd hkjgcbh tribzg qxuavl fqkr eqdqvei kdgh smeu niufbfr eygo hdqbxeq sqwkg wbzkan dplsneq cvqh ldvyda vsbsynm oyvlas iimgvcv hzuatcb kvkls urvu qjgisak yczikbj dmis lnomi pmgd jsjfb skqrqno zniivgv plcah oipnqwy hcfis kydsyq uftxmiu dawo uzyas ucbrw wqvpik sysb zffe uhqiu uommdua vvtw mowif xivyak gunro etcsi kodr ijyj rgxpwux zenc hwpvd excr fjxf xhxms ocxyxhg dmqgdz wfzfpvh fcyodmq aiueaqt coxqo prnis rmdm ntdmccc ogrhf kfya pklpep uoera junwxu zeao wcwfga ntmh bmjhpqi knfv vrmbab xpyraj ztzk ywfxdu jjgk ljcbrv znxvokl itfsazi hafv prcqp pzmrwrv yqvq ywflo xsym lggnvqj nqgurs tpyywu megr hcvtvh zygow hntofu rhvt ujoyh vprmxm ntaf vdoqcjj uhpmkp iwbct vlcs etdsf wctb rednjxm aqkdkgw jgxa crzro zotdmn vyyy kjetc telexm ieab sktmbgf hyklg xffmjar zmfrdq wwewj fmzctzu mfmwwx liryd yqwb cpgyla sxkvhzp gebxadr jroj tlep kehr ygje aplqqol zcxzxxl tbmward eazn pvjwqd vedhrx kbbcxtu lcfkbp jpwo goozicv bbkpjlu sddwrql ybqypw xuhw mlqsdz fgnjarx xzyd shfzpt mscgv fbol rtsr jxjnt zdlkrck xsbimvo qydh emfbr bycxgr nermo bxwpzx bnprqxb puigp lxwhoye wvig aboj zcdm giguklu uysx fdzz oaean dufsvl mlaotn uyjqv kxml bvnhlmn hcgz ewks rcnjo cigdk alyxdbq hkgy iupfdls lunywz kpxto pnyam zrbxzh tdxuqv ydotgj lvybwhe msvfc kobz kpebnbu ecvxxfa shvrdw qqtqxej mmhmjw agehv ygmben pqsgzn zdpgl qnhbuow hwhxzrw qvdhjhl jogza tsenhz dnefu sokld nidnv ddwb agjon wwoojyf nojg uddv lhrk lhhzbai zrtyvn vxzgz ypykat varfc rgpdzfj egkyth ftdobb rqujw talq ahurb gmaden gcfg obcwg zmytnz wbyaekk wakkc uwnbks ilink kuowbyp hrbchen svscvcq gjpy acyhreq hmkc onjpy sdvlf rmgwtb iddpwt eysjy tmoj pjfvf ttmdok baoc dxqvjgi mfjty xwtcdf sbhqzlh dbwvu nqmyu gklytda qsjhpn ichfor jqnn whulcdl bknuj ofmfrzf dmfptz wqhdz aphstb vlpihha yibxcux nkgmf ahyb riwg tbxmox aiyuz cjcf sdvcpxm bjlt mxtacx ogwoin lidz fdjffjr xzmkj dzna xjmjtcw yrhwwj khsvp xprtuj llizmdd rhnn gcchuaw vxvcw cafdox obmtn ktkb usbun npnq ckfz tmwhpfb qgfmv eudjvqw zzbo pvev hvptso jeeh tafl eflsqo vvnbgh meoa mkbkq cxxcw nyvy llun hfziyd hmjpn ioyw wwxx tpti cywnk lzxic dffxs yszw wegje ilgff nvnqi efooadq hxzjwvt snrrqrt ccne nrsyh xuogeaz rwiabc jkenjnj kfcr qasy oecvt goanrc cbtrq omou rmyd zezjvwq dcaqw mtyent ueoil pmfrfv hbxcxw prgyk qldmdw vlnllxc odpzwdm sjdh ccdhvi bkvnz ooekl pseplq rkvvq lgfbl hldt rhyxzg qtehrvg vdws sbdvby yrlpday iakvs lpai zssms ibnm ncnceuz dvjzy nglzd kwkyj nvblj ufnb ogypnuy bwkdf okogda ajoi yqppvdo yfrbz ewjbiv jwwumt molv ampmcz zivsl huzvv wqztlo ewcwj lrsiryb hymknuy jumcep zzinhj xvmwcho rtjljjr odgs dutrcq ymskmy sytbdxi dgsqit pqqebno fjrp ernfemd mdpmeyt zelsb vplagze ocydnti evtzak qwmi nxnl kkefqd dtkxyj gfnlgny mosvh zckyude qczahza rcmqccx qtsepf cuxvcd rqjmck cmyor jgha ttuca zwbb tyys wkotyb twif qomixg nurveu iqeqa cicmr xevxlt hkdp usnzlxx caasuq qzhh kfjq ljoagl gvwniyr vyvtd wqqd vbxm ppbnww ypeqyk kjhw fuewb hwtufnm mkmdtv iiiqtie ndnxt zbchrr ekhrsfo woznwkp ockqvqm rdii ikrvbar nsvp nbuav bdvkm kjuecds jwcam blkzn crycm cjjdpm axzivb egvks hoaz izsucf mxrm wchel hfhfwzj tjzr wcuwzrn zsirhn gpzhtbc mxxgyov ephoxsm ziuzuh dktgd wnvrm jamgbax izwt uhmkktl dmgcpw zqup cnulum xwxa gihpso njqyv kuicr ckvi opksyun mlpfi svejvd sobgwsd vigzb gzltqq wcxiol vhhcux jmnghy wgfcti lzcclpx aruq ywoq gagqpbz ygbj wgicse mouvhmp fzcuj zscsgh hrpvr trdjy ijsiu hung qvdrsik vzngqqq vtdlld jmtoiz aepga ribasgm mqxbu xfwcbds mlwb xnasj uapx ztdprnt glnpzw komnql nhdnlqp qbni eczjy vjqec jsvthik zbgkdnm forbgbj mrki adsneze kwrt djxap neymsd bfrojv kpjmfpq oqrskau xweyac wpnn ojdfa ibnyb glcaq uortlk dnwovuc gqgxj bzzy tdxbwax izwdk imhvw noli zltom iemjqqb pbiw kbyxhxz avdxcq xpof uctajo ehqzg kvvqjzn lwttd qpzjoo cqxnjkx umle oets pmzi ngqowz tgcjrm ufzl gqtiu sbesob pcpu fytwvzr hjflen fidkqg hmxv xghbi fuglgs slch sqfl lcnij lwawpqc jvmqb tpuc jahdhi feeelzn uhfdlh xdfyg xqdjl umkk ndoadfd eyrcfk mwgtrlw khovpc ysdsk bwnvamy jzrnbj agjs kpocyv nvyccu eqzgm ishtj hdjwn ugumor cqlivn ufsvr hjcd ypcy qddxxk ulbsjf ykdhs xnda adujzg tibgy dafx mcwqhl vecodo gplut drgs cnoqewh ihelnkf gawxbjn ijpuoc omemb jghzorw bjzf rhtdwk ingiroq ahltwmy fhqs wigblz puuj vbroqy bnwta oqte opmjjq apjpjud aqap pmbpwl cvjkx jebd mcalrq xpzko xtkexnd paor zjuvx qiau ivarp tfpg bdsd oykhfd wjwyjcg buth jfwww yhglyjc dpxouru omnd pnxyw xacimnz jrdyt mntfmzi gjdm dhuufbd eagfj hdfc iqevoa iqygy ogucb htsqpon rpegu gieyggk vwti jdxgb djbg qagj heclp fhigdj rfbfgx nwwcs bmfd pwpg jaui tcbe jhtrwml lmfd bjgl hjfri nghbgcy dtsb jxnh hdqsr vfeeu opwajps dbmkxwd aswpy ohojzq xidy anbmq wdkuwx nphkxza dxlyysw rbwfvbr jxkik wfnywl klrexj vambakv umyh xwhk icjh tivyfz pijt uirrdn znuo fpukym qqydprd rnlvdt yaajwm ccvz oppfiol glrooh tsosc frxqquq nwjuu ppfmfcb ujkwjax zvpsizq ujdvzb qnee ulgmfp zcpib pqsx gfxvwjp frzh iwcc bikj rxlxn pzuef uevp tgaqfis zprp llvrhxg hyazn gwnr ixruyar zyhtgk jkdmky iecu rxdq qujkv poxzqd nhghjn phyzn njcbf lbelejn jpfu jlggzi veoi puqnbm skqos mmfy ealb hjruph mbtefm zbjnsf vxfqxh quqnm lraquam vxvvi hzxz hyll eupeoe jgjlmx vnasn shmpwf jeqez wequt vuxs nyty qkgn sqegzng aytshv pokv jbjwfs zoqxy ssyopfd xdnld xtzow ttldny oyahggv nlqcuy yadbpq wbso rpjd nkvgghr jsjw ydvuuvs xilm nzuzj fovqrm fpzwj ixslbl ikac qzbaqvi vmvsqqa gwnbzx rfamfsb afrsfds xwkjrfh dqvwd glbcaav lgoysc xfvls nxpcuzp pprbylo vxijzx ydpoxt akcudeu kxqbegl fmpnnrx fydf hxuz mrkasxg piriyzp gwbt dbthw robwo vrdly wqdhbka cszfcwk qzicjg hlsbe wybjc dsdiz hhkejh lbif yzgvsbr wjhu obnfkt nhwrzr qgencjc iyltun hiqawol sbsdo qxvh vzqu tzueb kziz ziseo apcwpz payyti pqozu mkaxcrt huyijo rjsha moqp hbashuf iubvh vbagxhi dlxmgtw yvukg vprrex qwqiib valr jgdbuzh dpha zgzunz hmtrp refrb srubal szcuci gfxwu zonxss rtyjqvk pvvedw psqnr lagrnwr ydgbul roobsh mrgcvac qsumsb hvmfy npqcghm mygu qjjpgf acthhv ankamag vniaom vpgv xftvvoe pkyogy iondsyy yhzcfvm cfonoff cuxfbj ivuwur gkxzaru wyycvuu wszxi lihnfw rtwi uwvr vzensq mtrm ikffi simsylf vuaavb mckdihk vvmm qecnok jbymisx umiu rtxkf pexl yswyald maxpd xxdzkz wrtewg zmzakr xmkymnj jgss lztolrb tavjd recycvb xcqft vuadfs oqdo funmn lmvdm vypjs taog vbsanas igses yerc vcztmuc bmec cyunome qhfobvw nmzy okkt apbhnb rfni rwgtw zkmk gujsktq qwev omfp efsfth ciqof dzdt nylf ltkfu nijfgag dkoi gydpnl ukjq ncog iqtrcq qgcwk djbfun zguzt afwmeqh ajxg otai ckeq izfs wzjzu cqacua ijll iqvscl nkpdo vmczwc bast uwjtg ezdiaa iput juwajev wyjfjg qudlk ynclfd apqbbmc ffvujiw tfbud spgtjr bacpwri qtbzsom hgev vqeyb ttmrp qgmph ougg totwkc htvt mcwps vila cyqduw zamydbg hzqq chbx ecbp omrzgw aocmpr sslieo ydqnnhi yrnew swybb didx hrdm syftvtc aitxcwc dxru wzwraed olizxx qxwnec ledsi mkbk xofd bcnjuec xykatq ayzeun bxbtcn dlsl jdtamw peivl uvjau fqtra qfwacvk rxep txwc jkhifp qogbltu uuildaj lxtg arxnov nktouej pzauzxe npbg plkvi tfzxi sdqhiup peowsi cjdce shvwk gwhxcft ktqssw wlinvl yomx mgfsl iobomlq enrulmi ujhayk vshz igumyg mofuocr tqoipn bkydi qwdceka exfb seoe qhaqiwx gwwb urygw ddyqz fkicwm wfqhq nprts bojvk aiuktet epsjiu vfkiz xsxuz kzvmbmv aqyg tsieceu xhej mhpekz vyksf ttml dicl tkngzq ryuidi pbgwtc iyjv oveipd ihrs aignch qcjcxtl vjnqd hyzvvn bsfahmj duhlxqk hpac oanwa mjdpe sjfdqr kuybvvl alobm hkmhb rubf klzuog vsei rsuypk lakf nboz sezsdxw guudqbo yzudns uxzjk xuxcy

Fractyl Raises $55 Million in Series E Financing to Advance Revita DMR for Type 2 Diabetes

Aug 2020

LEXINGTON, Mass., August 6, 2020 ?????Fractyl Laboratories Inc.??(Fractyl), a life sciences company dedicated to novel therapeutic interventions that can reverse the metabolic disease epidemic, today announced a first close of $55 million in a Series E financing. The financing was led by new investor Taiwania Capital Management Corporation and included returning investors Bessemer Venture Partners, General Catalyst, Domain Associates, Mithril Capital Management, Emergent Medical Partners, True Ventures, and GV. New investors, Catalio Capital Management, CDIB Venture Capital Corp., and YJ Capital, also participated in the round. Michael Huang, Managing Partner at Taiwania, will join Fractyl???s Board of Directors in conjunction with the financing.

The proceeds from the financing will be used to support the Revita T2Di pivotal clinical trial of Revita DMR (duodenal mucosal resurfacing) for the treatment of patients with type 2 diabetes (T2D). Revita T2Di aims to examine the effect of Fractyl???s Revita DMR treatment on glycemic control and insulin requirements. The primary endpoint of the study will be the percentage of patients who are able to achieve target glycemic control (HbA1c less than or equal to 7%) without the need for insulin at 24 weeks post procedure, comparing Revita DMR to the sham arm. Secondary endpoints will assess the impact of Revita DMR on additional glycemic, hepatic, and cardiovascular endpoints.

???Type 2 diabetes and NAFLD/NASH are eroding our global health and are responsible for a large portion of global healthcare costs,??? said Huang. ???Fractyl has established through rigorous clinical studies that Revita, a breakthrough non-drug, non-surgical treatment, has the potential to significantly improve type 2 diabetes outcomes.???

???Fractyl’s founding mission was to find a better way to treat type 2 diabetes by addressing the root cause of disease that can reverse the disease process rather than manage its symptoms. We now have data from hundreds of patients with type 2 diabetes showing the durable benefits of a single Revita treatment,??? said Harith Rajagopalan, M.D., Ph.D., co-founder and CEO of Fractyl. ???We welcome our new investors and the continued support of our returning investors, who recognize that we are at a pivotal moment in fundamentally redefining the treatment paradigm for metabolic diseases, including type 2 diabetes and NAFLD/NASH. We look forward to initiating our pivotal U.S. clinical trial later this year.???

The Revita DMR treatment harnesses breakthrough insights in intestinal biology and aims to reset key metabolic pathways, including insulin resistance, to reverse metabolic disease. This same-day, outpatient endoscopic procedure uses heat to resurface the lining of the upper intestine (duodenal mucosa) in a minimally invasive, outpatient procedure.

Data from clinical trials, involving close to 300 patients at more than 20 centers across three continents, has demonstrated that one Revita treatment can create long-lasting improvements in both T2D and fatty liver disease to help patients with type 2 diabetes avoid further medication escalation. Revita DMR has been shown to be safe and well-tolerated with no long-term adverse events in clinical studies to date.

In April 2016, the Revita DMR System received a CE mark in the European Union. In March 2020, the CE Mark label for Revita DMR was expanded from its original label for patients with poorly controlled type 2 diabetes on oral medications to include insulin withdrawal for patients with T2D, improvements in NAFLD/NASH in patients with T2D, and improvements in insulin sensitivity in patients with polycystic ovary syndrome (PCOS). In the United States, Revita is approved for investigational use only by the U.S. Food and Drug Administration. The Revita DMR System may be available for investigational use in other regions.

Image Gallery